Skip to main content
main-content

Genitourinary cancers

News

06-07-2020 | FDA | News

Maintenance avelumab approved for advanced urothelial carcinoma after platinum chemotherapy

Read more on this US FDA announcement here

03-07-2020 | Prostate cancer | News

Updated ESMO prostate cancer guidelines released

Click through for more information on these Clinical Practice Guidelines

03-07-2020 | COVID-19 | News

Potential for anticancer, COVID-19 drug interactions highlighted

A French team has drawn attention to the potential for drug–drug interactions between anticancer medications and agents being used or tested for the treatment of COVID-19.

30-06-2020 | Renal cell carcinoma | News

Salvage nivolumab–ipilimumab shows potential for some metastatic RCC patients

The combination of nivolumab and ipilimumab demonstrates antitumor activity and acceptable toxicity in patients with metastatic renal cell carcinoma previously exposed to PD-1 or PD-L1 inhibitors, say the authors of a chart review.

25-06-2020 | Urothelial cancer | News

Switch maintenance pembrolizumab improves metastatic UC outcomes

Switch maintenance pembrolizumab prolongs progression-free survival versus placebo in patients with metastatic urothelial cancer who have achieved at least stable disease with first-line platinum-based chemotherapy, phase 2 study data show.

24-06-2020 | ASCO 2020 | Conference coverage | News

Antiandrogen therapy boosts nonmetastatic CRPC survival

Adding an androgen receptor inhibitor to androgen deprivation therapy significantly improves the overall survival of men with nonmetastatic castration-resistant prostate cancer, according to results from three trials.

19-06-2020 | FDA | News

Pembrolizumab approved for advanced TMB-H solid tumors

Read more on this US FDA decision here

17-06-2020 | ASCO 2020 | Conference coverage | News

Immunotherapy de-escalation in advanced RCC not feasible yet

Results from two studies presented at the virtual 2020 ASCO Annual Meeting suggest that the strategy of using single-agent nivolumab followed by response-adaptive or salvage add-on ipilimumab cannot be recommended for patients with advanced renal cell carcinoma.

This independent news story was supported by an educational grant from Pfizer and Merck KGa

16-06-2020 | ASCO 2020 | Conference coverage | News

FRACTION-RCC suggests nivolumab–ipilimumab benefit for some ICI-treated RCC patients

Initial results from the Fast Real-Time Assessment of Combination Therapies in Immuno-Oncology trial suggest that some patients with advanced renal cell carcinoma may benefit from nivolumab plus ipilimumab after immune checkpoint inhibitor therapy.

This independent news story was supported by an educational grant from Pfizer and Merck KGa

12-06-2020 | ASCO 2020 | Conference coverage | News

RCC studies identify biomarkers of PD-1 inhibitor outcomes

Analyses of the CheckMate 025 and KEYNOTE-427 trials of nivolumab and pembrolizumab, respectively, have identified biomarkers associated with response to the individual agents in patients with advanced renal cell carcinoma.

This independent news story was supported by an educational grant from Pfizer and Merck KGa

12-06-2020 | ASCO 2020 | Conference coverage | News

Second-line lenvatinib–pembrolizumab shows promise for metastatic ccRCC

Research suggests that patients with metastatic clear cell renal cell carcinoma with disease progression after immune checkpoint inhibitor therapy may benefit from the combination of lenvatinib and pembrolizumab.

This independent news story was supported by an educational grant from Pfizer and Merck KGa

11-06-2020 | ASCO 2020 | Conference coverage | News

CONDOR: 18F-DCFPyL PET diagnoses biochemically recurrent prostate cancer

Positron-emission tomography using the novel prostate-specific membrane antigen targeted 18F-DCFPyL tracer shows “excellent diagnostic performance” in men with biochemically recurrent prostate cancer, researchers report.

10-06-2020 | ASCO 2020 | News

Cabozantinib–atezolizumab duo shows urothelial cancer potential in COSMIC-021 study

The combination of cabozantinib and atezolizumab has “encouraging clinical activity” and acceptable tolerability in previously treated patients with advanced urothelial carcinoma, say the COSMIC-021 investigators.

09-06-2020 | ASCO 2020 | News

KEYNOTE-426 update ‘continues to support’ pembrolizumab plus axitinib

For patients with treatment-naïve advanced renal cell carcinoma, pembrolizumab plus axitinib offers superior overall survival to sunitinib, confirms an updated analysis from the KEYNOTE-426 trial.

This independent news story was supported by an educational grant from Pfizer and Merck KGaA

04-06-2020 | ASCO 2020 | News

HIF-2α inhibition ‘promising’ for von Hippel–Lindau disease-associated RCC

Findings from an open-label phase 2 study suggest the first-in-class HIF-2α inhibitor MK-6482 has “promising efficacy and tolerability” in the treatment of renal cell carcinoma associated with von Hippel–Lindau disease.

02-06-2020 | ASCO 2020 | News

Relugolix may offer better testosterone suppression than leuprolide

Men with advanced prostate cancer who receive the gonadotropin-releasing hormone antagonist relugolix are more likely to have sustained suppression of testosterone than those treated with leuprolide acetate, HERO trial data show.

01-06-2020 | ASCO 2020 | News

IMvigor010: No atezolizumab benefit for muscle-invasive urothelial carcinoma

For patients with high-risk muscle invasive urothelial carcinoma, adjuvant atezolizumab does not significantly extend disease-free survival compared with observation alone, the IMvigor010 investigators say.

30-05-2020 | ASCO 2020 | News

Maintenance avelumab ‘new standard of care’ for advanced urothelial cancer

The JAVELIN Bladder 100 trial has shown a significant improvement in the overall survival of advanced urothelial cancer patients with the addition of avelumab to best supportive care in the maintenance setting.

29-05-2020 | FDA | News

FDA approves rucaparib, olaparib for mutated metastatic CRPC

Read more on these decisions

27-05-2020 | Prostate cancer | Highlight | News

Data question ADT omission when using EBRT plus brachytherapy boost

Adding androgen deprivation therapy to external beam radiotherapy may result in better survival than adding a brachytherapy boost in men with intermediate- and high-risk prostate cancer, network meta-analysis data suggest.

Image Credits